U.S. Sen. Dave McCormick (R., Pa.) has joined fellow Senate Republicans in signing on to a letter urging top health officials in the Trump administration to rescind approval for a drug used in one of the most common methods of abortion.
In a letter to Health and Human Services Secretary Robert F. Kennedy Jr. and FDA Commissioner Marty Makary earlier this month, the Republican senators recommended, among other things, that officials reevaluate the safety of mifepristone, one of two pills commonly used in a medication abortion, and suspend the distribution of the drug and its generic versions, saying it should be considered an “imminent hazard” at the federal level.
“Today, your agencies have all the information they need to bring an end to previous Democrat administrations’ abortion drug regulations while a comprehensive review is conducted,” the Republicans wrote in the letter.
Only two Senate Republicans, Sens. Lisa Murkowski (R., Alaska) and Susan Collins (R., Maine), did not sign the letter.
Mifepristone is considered safe and effective and is used to terminate early-stage pregnancies and manage miscarriages, according to the American Medical Association. It received initial approval from the Food and Drug Administration in September 2000.
McCormick’s signature on the letter could signal a change in how the Pennsylvania Republican views abortion regulation. During his campaign last fall, McCormick said during a debate that he wants to leave regulation to individual states, which has been the status quo since the U.S. Supreme Court overturned Roe v. Wade in 2022. His backing of the letter, which encourages sweeping policy decisions at the national level, suggests otherwise.
Representatives for McCormick did not return a request for comment.
Last month, Kennedy said the FDA is reviewing the safety of mifepristone.
“By law, the FDA has very limited discretion in deciding whether to approve a generic drug, and the FDA’s approval of a generic mifepristone is not an endorsement of the product. HHS remains committed to its study of the reported adverse effects of mifepristone,” White House spokesperson Kush Desai said in a statement to The Inquirer.
Medical abortions, where mifepristone is used as part of a two-drug regimen along with misoprostol, account for more than half of all abortions performed in the U.S., according to the Cleveland Clinic in 2024.
Should the FDA revoke it’s approval of mifepristone, medical abortions won’t be eradicated. Medication abortions are possible using just misoprostol, but the method is less effective, according to a 2021 report from the American Family Physician.
In addition to their safety concerns, Senate Republicans are also urging Kennedy and Makary to suspend approving new generic versions of mifepristone awaiting the results of a safety review of the Risk Evaluation and Mitigation Strategies (REMS) for the drug. REMS are safety programs for certain medications as required by the FDA.
The Republicans are also urging the federal government to require mifepristone and its generic versions to be distributed in person, not through mail, and not at a pharmacy.
The letter also claims that the U.S. has an “‘abortion-on-demand’ culture,” referring to the accessibility of accessing mifepristone through mail. But, according to Planned Parenthood, a telehealth call is required before any pill is shipped.